Q: Is there a vaccine or treatment for Hantavirus?

There is no FDA-approved vaccine or specific antiviral treatment for hantavirus infections in most countries. South Korea and China have approved vaccines against Hantaan and Seoul virus strains for use domestically. Treatment is supportive: supplemental oxygen, mechanical ventilation for HPS patients, and dialysis for severe HFRS. Early hospitalisation significantly improves survival odds. Ribavirin has been used experimentally for HFRS with limited evidence.

Q: Who is at risk of Hantavirus infection?

Anyone who comes into contact with infected rodents or their environments is at risk. Higher-risk groups include: rural or outdoor workers (farmers, forestry, construction), campers and hikers in endemic areas, travellers to Patagonia, rural South America, or East/Central Asia, and people cleaning or entering rodent-infested buildings. In the 2026 cruise ship outbreak, expedition tourists visiting remote South Atlantic rodent habitats were exposed.

Q: How can I protect myself from Hantavirus?

Key precautions: avoid disturbing rodent nests or droppings; ventilate enclosed spaces before entering; use an N95 respirator and gloves when cleaning potentially contaminated areas; wet droppings with a 10% bleach solution before removing (never dry-sweep or vacuum); store food in sealed containers; seal gaps in buildings to prevent rodent entry; and avoid sleeping directly on bare ground in endemic areas when camping.

Q: How common is Hantavirus globally?

Globally, HFRS causes an estimated 60,000+ cases annually, the vast majority in China and Russia. HPS in the Americas accounts for 200–400 cases per year. The United States has recorded fewer than 1,000 HPS cases since the disease was first identified in 1993. Argentina and Chile each record 50–150 annual cases. Hantavirus is present on every continent except Antarctica, though strains vary greatly in severity.

Question 1

What is Hantavirus?

Accepted Answer

Hantavirus is a family of RNA viruses carried by rodents worldwide. There are over 40 known strains. Humans are typically infected by breathing in air contaminated with the urine, faeces, or saliva of infected rodents. The virus causes two main disease syndromes: Hantavirus Pulmonary Syndrome (HPS), which primarily affects the lungs, and Hemorrhagic Fever with Renal Syndrome (HFRS), which damages the kidneys.

Question 2

What are the symptoms of Hantavirus infection?

Accepted Answer

Early symptoms (days 1–5) resemble flu: fever, fatigue, muscle aches, headaches, dizziness, and sometimes nausea or abdominal pain. For HPS, symptoms rapidly progress to coughing, shortness of breath, and fluid build-up in the lungs — a medical emergency. For HFRS, symptoms include intense headache, back and abdominal pain, kidney failure, and haemorrhage. There is no specific antiviral treatment; supportive care including mechanical ventilation may be required.

Question 3

How does Hantavirus spread?

Accepted Answer

The primary route is inhalation of aerosolised rodent excreta (urine, droppings, saliva). This can happen when disturbing nesting material, sweeping, or entering rodent-infested spaces. Most hantavirus strains do not spread person-to-person. The critical exception is Andes virus (ANDV), found in South America, which has been documented spreading directly between humans — the only known hantavirus with this capability.

Question 4

What makes the 2026 MV Hondius outbreak unusual?

Accepted Answer

The outbreak is caused by Andes virus and has occurred aboard an expedition cruise ship with passengers from multiple countries, making contact tracing complex. Andes virus can transmit person-to-person, distinguishing this cluster from typical hantavirus events. Three deaths have been confirmed from seven cases (a ~43% case fatality rate in this cluster). It is among the first documented shipboard hantavirus outbreaks, and involves international epidemiological coordination between Argentina, South Africa, the Netherlands, and Germany.

Question 5

How deadly is Hantavirus?

Accepted Answer

It depends on the strain and syndrome. HPS caused by Sin Nombre virus in the USA has a case fatality rate of approximately 36%. Andes virus outbreaks have seen rates from 25–50%. HFRS caused by Puumala virus in Europe is generally mild (<0.1% CFR), while Hantaan virus in Asia carries a 1–15% CFR. Overall, hantavirus is considered rare but severe — the 2026 MV Hondius outbreak is tracking at roughly 43% CFR.

Question 6

Is there a vaccine or treatment for Hantavirus?

Accepted Answer

There is no FDA-approved vaccine or specific antiviral treatment for hantavirus infections in most countries. South Korea and China have approved vaccines against Hantaan and Seoul virus strains for use domestically. Treatment is supportive: supplemental oxygen, mechanical ventilation for HPS patients, and dialysis for severe HFRS. Early hospitalisation significantly improves survival odds. Ribavirin has been used experimentally for HFRS with limited evidence.

Question 7

Who is at risk of Hantavirus infection?

Accepted Answer

Anyone who comes into contact with infected rodents or their environments is at risk. Higher-risk groups include: rural or outdoor workers (farmers, forestry, construction), campers and hikers in endemic areas, travellers to Patagonia, rural South America, or East/Central Asia, and people cleaning or entering rodent-infested buildings. In the 2026 cruise ship outbreak, expedition tourists visiting remote South Atlantic rodent habitats were exposed.

Question 8

How can I protect myself from Hantavirus?

Accepted Answer

Key precautions: avoid disturbing rodent nests or droppings; ventilate enclosed spaces before entering; use an N95 respirator and gloves when cleaning potentially contaminated areas; wet droppings with a 10% bleach solution before removing (never dry-sweep or vacuum); store food in sealed containers; seal gaps in buildings to prevent rodent entry; and avoid sleeping directly on bare ground in endemic areas when camping.

Question 9

How common is Hantavirus globally?

Accepted Answer

Globally, HFRS causes an estimated 60,000+ cases annually, the vast majority in China and Russia. HPS in the Americas accounts for 200–400 cases per year. The United States has recorded fewer than 1,000 HPS cases since the disease was first identified in 1993. Argentina and Chile each record 50–150 annual cases. Hantavirus is present on every continent except Antarctica, though strains vary greatly in severity.

Country	Syndrome / Strain	Annual Cases	CFR	Status
Argentina South America 28 deaths in 2025; 2026 MV Hondius outbreak linked to Ushuaia departure	HPS — Andes virus (ANDV)	80–150	25–40%	Active
South Africa Africa 1 critical patient (2026 MV Hondius); NICD confirmed PCR May 2	HPS — Andes virus (imported)	Rare (imported)	~36%	Active
United States North America Fewer than 1,000 total cases since 1993; endemic in western US	Hantavirus Pulmonary Syndrome (HPS)	10–50	36%	High
Chile South America	HPS — Andes virus (ANDV)	50–100	30%	High
Brazil South America	HPS — Juquitiba / Araraquara	100–200	40%	High
China East Asia	Hemorrhagic Fever with Renal Syndrome (HFRS)	~10,000	1–15%	High
Russia Europe / Russia	HFRS — Puumala / Hantaan	5,000–10,000	0.1–1%	High
Finland Northern Europe	HFRS — Puumala virus	1,000–3,000	<0.1%	Moderate
Sweden Northern Europe	HFRS — Puumala virus	200–400	<0.1%	Moderate

Hantavirus Live Tracker 2026

MV Hondius

2026 Outbreak Timeline — MV Hondius

WHO Hantavirus Updates

Global Statistics

Regional Breakdown

Syndromes

Hantavirus Pulmonary Syndrome (HPS)

Hemorrhagic Fever with Renal Syndrome (HFRS)

Historical Outbreaks

Frequently Asked Questions